Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Translational Development Acquisition (TDAC) Shares Outstanding (Diluted Average) (2023 - 2026)

Translational Development Acquisition's Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $4.7 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) changed 0.0% to $4.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.7 million, a 0.0% change, with the full-year FY2025 number at $4.7 million, changed 0.0% from a year prior.
  • Shares Outstanding (Diluted Average) came in at $4.7 million for Q1 2026, roughly flat from $4.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $4.7 million in Q4 2024, with the low at $4.0 million in Q4 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $4.5 million across 4 years, with a median of $4.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 15.0% in 2024 and later changed 0.0% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $4.0 million in 2023, then increased by 15.0% to $4.7 million in 2024, then changed by 0.0% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TDAC at $4.7 million in Q1 2026, $4.7 million in Q4 2025, and $4.7 million in Q3 2025.